NETRIS Pharma

NETRIS Pharma is a pioneering French biotech focused on overcoming cancer treatment resistance by targeting the novel Netrin-1 pathway. Its lead asset, NP137, is an anti-Netrin-1 monoclonal antibody with demonstrated safety and anti-tumoral activity in over 300 patients across several solid tumors. The company leverages a deep scientific foundation from its parent research centers and strategic partnerships with industry leaders like MSD to advance its pipeline in high unmet need cancers. Its integrated model within a top-tier cancer center provides a significant advantage in translational and clinical development.

Platform targeting the Netrin-1 pathway and dependence receptors to reactivate tumor-suppressive cell death and overcome treatment resistance in cancer.

NETRIS is the pioneer in clinically targeting Netrin-1, with no direct competitors at a similar stage. Indirect competition comes from other companies developing therapies to overcome immunotherapy or chemotherapy resistance through different mechanisms (e.g., TME modulators, alternative cell death inducers).